A Phase 1/Phase 2 Study of Polyvalent Pneumococcal Conjugate Vaccine (pPCV) in Adults

Condition:   Pneumonia, Pneumococcal Interventions:   Drug: pPCV;   Biological: Pneumovax™23 Sponsor:   Merck Sharp & Dohme Corp. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

[MSF] New Delhi/New York -Gavi, the Vaccine Alliance should immediately stop giving millions of dollars in financial incentives to pharmaceutical companies Pfizer and GlaxoSmithKline (GSK) for the pneumococcal conjugate vaccine (PCV), said the international humanitarian organization Doctors Without Borders/M édecins Sans Frontières (MSF) ahead of the group's board meeting in New Delhi, India on December 4 and 5. Instead, Gavi should use the remaining US $262 million of the US $1.5 billion subsidy fund to support the ro
Source: AllAfrica News: Health and Medicine - Category: African Health Source Type: news
Conclusion: According to WHO-recommended thresholds for interpreting cost-effectiveness, introduction of PCV-13 for children under 5 years in the Islamic Republic of Iran would be cost-effective. PMID: 31774134 [PubMed - in process]
Source: Eastern Mediterranean Health Journal - Category: Middle East Health Tags: East Mediterr Health J Source Type: research
.
Source: Infectious Diseases - Category: Infectious Diseases Authors: Source Type: research
Pneumonia is one of the most common reasons patients over the age of 65 years present to the Emergency Department (ED). There is a 23-valent pneumococcal vaccine (23vPPV) available under the National Immunisation Program (NIP) with demonstrated 61 –71% effectiveness against Invasive Pneumococcal Disease (IPD), but only 51% of adults aged over 65 years are vaccinated in Australia.
Source: Australasian Emergency Nursing Journal - Category: Nursing Authors: Tags: Research paper Source Type: research
Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2019 Nov 22;68(46):1069-1075 Authors: Matanock A, Lee G, Gierke R, Kobayashi M, Leidner A, Pilishvili T Abstract Two pneumococcal vaccines are currently licensed for use in adults in the United States: a 13-valent pneumococcal conjugate vaccine (PCV13 [Prevnar 13, Pfizer, Inc.]) and a 23-valent pneumococcal polysaccharide vaccine (PPSV23 [Pneumovax 23, Merck and Co., Inc....
Source: MMWR Morb Mortal Wkl... - Category: Epidemiology Authors: Tags: MMWR Morb Mortal Wkly Rep Source Type: research
Objective: to evaluate the effect of conjugated pneumococcal vaccine Prevenar 13 on the course of COPD in combination with type 2 diabetes.The study included 76 patients with COPD III (40.8%) and COPD IV (59.2%) in combination with type 2 diabetes, 72 (94.7%) men and 4 (5.3%) women, averaga age 64.72 years. All patients were current or past smokers, the smoking index- 45.11. The duration of COPD was 8.71 years, the lasting of diabetes mellitus was 10.23 years. All patients were overweight, BMI=31.67 kg/m2. ±Before vaccination, patients reported severe clinical symptoms (CAT=27.99±3.79, CI 95% 19-36) and parti...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Monitoring airway disease Source Type: research
One of the extremely important problems of managing patients with COPD is to prevent exacerbations. It becomes particularly relevant in the run-up to or during a flu epidemic.Objective: To assess the clinical and economic efficacy of joint vaccine prophylaxis with conjugated pneumococcal vaccine (PCV13) and influenzal vaccine in patients with COPD.Material and methods: The study included 153 patients. They divided into three groups of observation. The 1 group (n = 53) - of patients vaccinated with PCV13. The 2 group (n=51) vaccinated with PCV13 and influenzal vaccine simultaneously or with an interval of not more than 2 we...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Airway pharmacology and treatment Source Type: research
Conclusions: The results gained in the survey revealed the insufficient level of physicians’ knowledge in management of patients with CAP. On the one hand, a number of issues need to be considered more carefully, on the other hand, educational activities have to be conducted among physicians of medical and preventive treatment facilities.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Medical education, web and internet Source Type: research
Aim: to study effectiveness of specific prevention of pneumococcal infection in patients with chronic lung diseases.Materials and Methods: to assess the clinical effectiveness of vaccination, special questionnaire was developed, which included an assessment of anamnesis during the year preceding vaccination and anamnesis of the underlying disease during the year after vaccination. 881 patients with chronic lung diseases were vaccinated.Results: vaccination against pneumococcus in patients with chronic lung diseases has significantly reduced the number of exacerbations of the underlying disease in patients aged 56-60years(R...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Respiratory infections Source Type: research
Background: Burden of community acquired pneumonia (CAP) in infants is high in India. Streptococcus pneumoniae is stated to be an common etiological agent for it. Hence Pneumococcal Conjugate Vaccination(PCV) has been introduced in India since 2017(phased-wise).Objective: To study effect of PCV on radiological findings of chest in infants hospitalized with WHO-defined CAP.Methods: Prospective hospital-based pneumonia surveillance is ongoing since 2015 in Lucknow &Etawah districts, Uttar Pradesh and Patna &Darbhanga districts, Bihar, India. Recruitments were done from a network of hospitals formed for project. Infan...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Paediatric respiratory epidemiology Source Type: research
More News: Meningitis Vaccine | Pneomococcal Vaccine | Pneumonia | Research | Study | Vaccines